Spontaneous and perturbation-based EEG cortical excitability markers are associated with plasma p-tau181 concentration in healthy middle-aged adults
In early-stage Alzheimer's disease (AD) amyloid-β (Aβ) deposition can induce neuronal hyperactivity, thereby potentially triggering activity-dependent neuronal secretion of phosphorylated tau (p-tau), ensuing tau aggregation and spread. Therefore, cortical excitability is a candidate biomarker for early AD detection. Moreover, lowering neuronal excitability could potentially complement strategies to reduce Aβ and tau buildup. There is, however, a lack of understanding of the relationship between cortical excitability and p-tau increase <i>in vivo</i>. Therefore, in a sample of 658 healthy middle-aged (between the ages of 40 and 65) participants of the Barcelona Brain Health Initiative cohort study, we examined the relation of blood-based tau, phosphorylated at amino acid 181 (p-tau181), reflecting neuronal p-tau secretion; neurofilament light chain (NfL), as a passively released control for p-tau181; and electroencephalography (EEG) markers of cortical excitability. A subsample of 47 participants also completed a controlled brain perturbation approach via transcranial magnetic stimulation (TMS) with concurrent EEG. Results show that both spontaneous (i.e., resting-state) and perturbation-based TMS-EEG markers, are associated with blood p-tau181, particularly in older individuals. The perturbation-based marker was a significantly more sensitive predictor of p-tau181 concentration than the spontaneous resting state EEG-based marker. The relationships observed are not present for the NfL control. These results show that relationships between p-tau181 and cortical excitability are present in healthy middle-aged subjects and that p-tau181 increases may reflect activity-dependent secretion.
Authors
- María Cabello‐Toscano (ORCID: https://orcid.org/0000-0001-5066-3476)
- María Redondo‐Camós (ORCID: https://orcid.org/0000-0002-3890-5070)
- Ruben Perellón‐Alfonso (ORCID: https://orcid.org/0000-0001-8647-3703)
- Lídia Mulet‐Pons (ORCID: https://orcid.org/0000-0002-8884-136X)
- Josep M. Tormos (ORCID: https://orcid.org/0000-0002-8764-2289)
- Selma Delgado‐Gallén
- Lídia Vaqué‐Alcázar (ORCID: https://orcid.org/0000-0002-6776-6559)
- David Bartrés‐Faz (ORCID: https://orcid.org/0000-0001-6020-4118)
- Álvaro Pascual‐Leone (ORCID: https://orcid.org/0000-0001-8975-0382)
- Goretti España‐Irla (ORCID: https://orcid.org/0000-0003-2525-6523)
- Indre Pileckyte (ORCID: https://orcid.org/0000-0001-8034-7028)
- Kilian Abellaneda‐Pérez (ORCID: https://orcid.org/0000-0001-6447-1248)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
- G. Cattaneo
- Javier Solana Sánchez (ORCID: https://orcid.org/0000-0003-0880-7856)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Northeastern University (US)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Universitat Pompeu Fabra (ES)
- Sahlgrenska University Hospital (SE)
- Hospital de Sant Pau (ES)
- Valencia Catholic University Saint Vincent Martyr (ES)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Institut Guttmann (ES)
- Hebrew SeniorLife (US)
- UK Dementia Research Institute (GB)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- National Hospital for Neurology and Neurosurgery (GB)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Institut de Recerca Sant Pau (ES)
- University College London (GB)
- Universitat de Barcelona (ES)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Heliyon
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e41118
- Citations
- 3
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Alzheimer's Association
- Familjen Erling-Perssons Stiftelse
- Cure Alzheimer's Fund
- Stiftelsen för Gamla Tjänarinnor
- EU Joint Programme – Neurodegenerative Disease Research
- National Institute for Health and Care Research
- University College London
- European Commission
- Hjärnfonden
- Vetenskapsrådet
- Ministerio de Ciencia e Innovación
- UK Dementia Research Institute
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
- National Institutes of Health
- HORIZON EUROPE Framework Programme